ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

被引：0
|
作者：
Sandborn, William J.
Vermeire, Severine
Peyrin-Biroulet, Laurent
Dubinsky, Marla C.
Panes, Julian
Yarur, Andres J.
Ritter, Timothy E.
Baert, Filip J.
Sloan, Sheldon
Cataldi, Fabio
Shan, Kevin
Rabbat, Christopher J.
Chiorean, Michael V.
Wolf, Douglas C.
Sands, Bruce E.
D'Haens, Geert
Danese, Silvio
Goetsch, Martina
Feagan, Brian G.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
968a
引用
收藏
页码：S1395 / S1395
页数：1
相关论文
共 50 条
  • [1] Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Sandborn, William J.
    D'Haens, Geert
    Panes, Julian
    Yarur, Andres
    Wolf, Douglas C.
    Ritter, Timothy E.
    Schreiber, Stefan
    Sloan, Sheldon
    Cataldi, Fabio
    Shan, Kevin
    Rabbat, Christopher J.
    Chiorean, Michael
    Baert, Filip
    Sands, Bruce E.
    Dubinsky, Marla C.
    Vermeire, Severine
    Goetsch, Martina
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S516 - S517
  • [2] Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
    Danese, Silvio
    Komori, H. Kiyomi
    Ryan, Rathi D.
    Cataldi, Fabio
    Lee, Caroline A.
    Goetsch, Martina
    Siegmund, Britta
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S673 - S673
  • [3] ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS
    Regueiro, Miguel D.
    Siegmund, Britta
    Yarur, Andres J.
    Steinwurz, Flavio
    Gecse, Krisztina
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Wu, Joseph
    Green, Jesse
    McDonnell, Aoibhinn
    Crosby, Catherine
    Lazin, Krisztina
    Branquinho, Diogo
    Modesto, Irene
    Abreu, Maria T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1105 - S1106
  • [4] Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
    Regueiro, M.
    Siegmund, B.
    Yarur, A.
    Steinwurz, F.
    Gecse, K. B.
    Goetsch, M.
    Bhattacharjee, A.
    Wu, J.
    Green, J.
    McDonnell, A.
    Crosby, C.
    Lazin, K.
    Branquinho, D. Ferreira
    Modesto, I.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 689 - 690
  • [5] Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Chaparro, M.
    Armuzzi, A.
    Irving, P. M.
    Allez, M.
    Dubinsky, M. C.
    Sands, B. E.
    Goetsch, M.
    Wang, W.
    Shan, K.
    Woolcott, J.
    Bartolome, L.
    Wosik, K.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I107 - I110
  • [6] EFFICACY OF ETRASIMOD ON SYMPTOMATIC RELIEF IN PATIENTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Chaparro, Maria
    Armuzzi, Alessandro
    Irving, Peter M.
    Allez, Matthieu
    Dubinsky, Marla C.
    Sands, Bruce E.
    Goetsch, Martina
    Wang, Wenjin
    Shan, Kevin
    Woolcott, John
    Bartolome, Lauren
    Wosik, Karolina
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S1099 - S1100
  • [7] Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Peyrin-Biroulet, L.
    Dubinsky, M. C.
    Sands, B. E.
    Panes, J.
    Schreiber, S.
    Reinisch, W.
    Feagan, B. G.
    Danese, S.
    Yarur, A.
    D'Haens, G.
    Goetsch, M.
    Wosik, K.
    Wu, J.
    Modesto, I.
    McDonnell, A.
    Bartolome, L.
    Rabbat, C. J.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 536 - 537
  • [8] EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ISOLATED PROCTITIS: A SUBGROUP ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Peyrin-Biroulet, Laurent
    Dubinsky, Marla C.
    Sands, Bruce E.
    Panes, Julian
    Schreiber, Stefan
    Reinisch, Walter
    Feagan, Brian G.
    Danese, Silvio
    Yarur, Andres J.
    D'Haens, Geert
    Goetsch, Martina
    Wosik, Karolina
    Wu, Joseph
    Modesto, Irene
    McDonnell, Aoibhinn
    Bartolome, Lauren
    Rabbat, Christopher J.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S1087 - S1087
  • [9] ACHIEVEMENT OF STRINGENT HISTOLOGIC AND COMPOSITE ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
    Magro, Fernando
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Danese, Silvio
    Jairath, Vipul
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Wu, Joseph
    Branquinho, Diogo
    Modesto, Irene
    Feagan, Brian G.
    GASTROENTEROLOGY, 2023, 164 (06) : S1092 - S1093
  • [10] Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
    Magro, F.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Danese, S.
    Jairath, V.
    Goetsch, M.
    Bhattacharjee, A.
    Wu, J.
    Branquinho, D. Ferreira
    Modesto, I.
    Feagan, B. G.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 728 - 729
12345